HKU Study Promises New Treatment For Influenza

"); jQuery("#212 h3").html("

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "http://newsstatic.rthk.hk/audios/mfile_1401896_1_20180615154932.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'http://news.rthk.hk/rthk/en/component/k2/1401896-20180615.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','http://news.rthk.hk/rthk/en/component/k2/1401896-20180615.htm', 'DCS.dcsqry', '' ); } } }); }); });
2018-06-15 HKT 17:53
Hong Kong University researchers say they've achieved a world first in the fight against influenza, by curing infected mice using a doctored version of the flu virus.
Lead researcher Yuen Kwok-yung said this new kind of treatment promises to be more effective than existing drugs like Tamiflu or Relenza, which are only effective when administered within days of the patient falling ill, and for which viruses can quickly develop resistance.
The new treatment effectively turns the flu virus against itself. Researchers cuts away certain key genes from the virus, which prevents it from replicating normally. This 'defective interfering gene' treatment, dubbed DIG3, is therefore resistant to mutation because the virus recognises it as one of its own.
"The cell is being cheated... it's treated as the normal influenza virus. And so we do not expect mutations to develop against the defective interfering genes", Yuen said.
Another researcher, Kelvin To, said their study is the "first time in the world that defective interfering gene has been successfully demonstrated to cure mice from influenza."
"In this study, we have tested H7N7 and H1N1, but we believe that it should theoretically be able to fight against other subtypes of influenza viruses as well," he added.
However, researchers caution that it can take decades of development, clinical trials and adjustments, costing billions of dollars, before the technology can lead to new drugs actually being introduced to the market.
"We have a patent, and we're waiting for investors and companies to develop [the treatment] further in clinical trials et cetera. And we hope that, with the government's emphasis on innovation and technology, there would be money coming in to develop this into a marketable drug one day", Yuen said.
Payoneer Completes Easylink Payment Acquisition, To Expand In China
Payoneer, a fintech company offering online money transfers and digital payment services, announced on 9 April 2024 tha... Read more
Adobe And Antom Partner To Enhance Digital Creativity Payments In Asia
Adobe and Antom, a provider of merchant payment and digitisation solutions under Ant International, announced a new col... Read more
HKMA Steps Up Against Digital Scams With Fresh Safeguards
The Hong Kong Monetary Authority (HKMA) announced “E-Banking Security ABC,” a series of new anti-digital fra... Read more
Staking-Enabled Bosera HashKey Ether ETF To Launch By End-April
Bosera International and HashKey Capital Limited announced the launch of the Bosera HashKey Virtual Asset Ether ETF on ... Read more
XTransfer Showcases Cross-Border Payment Solutions At AsiaWorld-Expo
XTransfer participated in the Global Sources Consumer Electronics Show 2025 at AsiaWorld-Expo on April 11, 2025, to pre... Read more
Bain Capital Aims To Raise US$9 Billion For New Asia Funds
Bain Capital is aiming to raise billions of US dollars for its upcoming Asia fund and a special situations fund in the... Read more